By Fineline Cube 
Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197), a Beijing-based pharmaceutical company, announced it has received marketing approval from the National Medical Products Administration (NMPA) for its CT-707, a second-generation ALK inhibitor. The approval allows CT-707 to be used in patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received treatment with an anaplastic lymphoma kinase (ALK) inhibitor.
Regulatory Approval Details
| Item | Detail |
|---|---|
| Company | Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197) |
| Regulatory Body | National Medical Products Administration (NMPA), China |
| Drug Name | CT-707 |
| Drug Class | Second-generation ALK inhibitor |
| Indication | ALK-positive locally advanced or metastatic NSCLC |
| Patient Population | Treatment-naïve (no prior ALK inhibitor therapy) |
| Approval Basis | Pivotal Phase III clinical study |
Clinical Trial Results – Phase III Study
| Efficacy Measure | CT-707 Performance | Clinical Significance |
|---|---|---|
| Progression-Free Survival (PFS) | Clinically meaningful improvement | Primary endpoint met |
| Objective Response Rate (ORR) | Statistically significant benefit | Key secondary endpoint |
| Duration of Response (DoR) | Extended response duration | Demonstrates sustained efficacy |
| Safety Profile | Favorable overall safety and tolerability | Manageable adverse events |
| Study Design | Pivotal Phase III, first-line setting | Head-to-head vs. standard of care |
The complete Phase III data demonstrates that CT-707 provides clinically meaningful benefits across all key efficacy measures in the first-line treatment setting for ALK-positive NSCLC.
Drug Profile & Competitive Positioning
- Molecule: CT-707 – second-generation ALK inhibitor
- Target Population: ALK-positive NSCLC patients (approximately 3-7% of all NSCLC cases)
- Treatment Setting: First-line therapy for treatment-naïve patients
- Generational Advantage: Second-generation inhibitors typically offer improved CNS penetration and activity against resistance mutations compared to first-generation agents like crizotinib
- Market Entry: Positions Shouyao Holdings in the competitive ALK inhibitor landscape alongside established players
Market Context & Competitive Landscape
| Competitor | Drug | Generation | Market Status in China |
|---|---|---|---|
| Pfizer | Crizotinib | First-generation | Approved, generic versions available |
| Roche | Alectinib | Second-generation | Approved, premium pricing |
| Novartis | Ceritinib | Second-generation | Approved |
| Takeda | Brigatinib | Second-generation | Approved |
| Shouyao Holdings | CT-707 | Second-generation | Newly approved |
- NSCLC Market Size: Lung cancer represents the most common cancer globally, with NSCLC accounting for approximately 85% of cases
- ALK-Positive Subset: Represents 3-7% of NSCLC patients, translating to thousands of eligible patients annually in China
- Treatment Paradigm: Second-generation ALK inhibitors have become the preferred first-line option due to superior efficacy and CNS activity
- Commercial Opportunity: Domestic development provides potential cost advantages over imported branded therapies
Strategic Implications
- Domestic Innovation: Represents another milestone in China’s growing capability to develop targeted oncology therapies
- Market Access: Local manufacturing and development may facilitate broader patient access through favorable pricing and reimbursement negotiations
- Competitive Differentiation: Specific efficacy and safety advantages over existing second-generation ALK inhibitors will determine market positioning
- Pipeline Validation: Success with CT-707 validates Shouyao Holdings’ oncology drug development capabilities
Forward-Looking Statements
This brief contains forward-looking statements regarding commercial potential, market opportunities, and competitive positioning. Actual results may differ due to risks including market adoption, pricing pressures, and competitive dynamics.-Fineline Info & Tech